Lipid Management for the Prevention of Cardiovascular Disease

被引：1
作者：
Schaefer, Juergen R. [1 ]
机构：
[1] Dr Pohl Stiftungsprof Prevent Cardiol Philipps Un, UKGM Standort Marburg, D-35033 Marburg, Germany
来源：
CURRENT PHARMACEUTICAL DESIGN | 2011年 / 17卷 / 09期
关键词：
Lipid lowering therapy; atherosclerosis; coronary artery disease; prevention; CORONARY STENOSIS PROGRESSION; AVERAGE CHOLESTEROL LEVELS; MYOCARDIAL-INFARCTION; COLESEVELAM HYDROCHLORIDE; STATIN THERAPY; SECONDARY PREVENTION; COMBINATION THERAPY; METABOLIC SYNDROME; LDL CHOLESTEROL; SIMVASTATIN;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the beneficial effect of statins in primary as well as secondary prevention. By this statins are the basic treatment in patients with coronary artery disease (CAD) or diabetes mellitus or both. In order to reach LDL - cholesterol target levels (LDL - cholesterol < 100 mg/dl) in patients with CAD the use of potent statins or a lipid lowering combination therapy might be necessary. In our days we are able to lower LDL-cholesterol by more than 50% with drug treatment, which should enable us to reach the optimal LDL-cholesterol level in most patients.
引用
收藏
页码：852 / 860
页数：9
相关论文
共 62 条
[1]  
AHMADI N, 2011, AM J CARDIOL 0117
[2]   Colesevelam hydrochloride: A novel bile acid-binding resin [J].
Aldridge, MA ;
Ito, MK .
ANNALS OF PHARMACOTHERAPY, 2001, 35 (7-8) :898-907
[3]  
AVITABILE N, 2011, EXPERT OPIN DRU 0119
[4]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[5]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[6]  
BAIGENT C, 2010, RESULTS STUDY HEART
[7]   Pravastatin - A review of its use in elderly patients [J].
Bang, LM ;
Goa, KL .
DRUGS & AGING, 2003, 20 (14) :1061-1082
[8]   The Role of Colesevelam Hydrochloride in Hypercholesterolemia and Type 2 Diabetes Mellitus [J].
Brunetti, Luigi ;
Hermes-DeSantis, Evelyn R. .
ANNALS OF PHARMACOTHERAPY, 2010, 44 (7-8) :1196-1206
[9]   The IDEAL cholesterol - Lower is better [J].
Cannon, CP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (19) :2492-2494
[10]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
1234567